On March 30, 2026, Aquestive Therapeutics, Inc. announced it successfully held a Type A meeting with the FDA regarding the resubmission of its New Drug Application for Anaphylm™ to treat allergic reactions, including anaphylaxis.
AI Assistant
AQUESTIVE THERAPEUTICS INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.